AstraZeneca Historical Cash Flow
| AZN Stock | 10,938 94.00 0.87% |
Analysis of AstraZeneca PLC cash flow over time is an excellent tool to project AstraZeneca PLC future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 177.9 M or Begin Period Cash Flow of 4.5 B as it is a great indicator of AstraZeneca PLC ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining AstraZeneca PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AstraZeneca PLC is a good buy for the upcoming year.
AstraZeneca |
About AstraZeneca Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in AstraZeneca balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which AstraZeneca's non-liquid assets can be easily converted into cash.
AstraZeneca PLC Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by AstraZeneca PLC to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of AstraZeneca PLC operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from AstraZeneca PLC's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into AstraZeneca PLC current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, AstraZeneca PLC's Depreciation is projected to increase significantly based on the last few years of reporting. The current year's Capital Expenditures is expected to grow to about 4.6 B, whereas Change In Cash is forecasted to decline to (327 M).
| 2022 | 2023 | 2024 | 2025 (projected) | Stock Based Compensation | 619M | 579M | 665.9M | 340.4M | Dividends Paid | 4.4B | 4.5B | 5.2B | 3.4B |
AstraZeneca PLC cash flow statement Correlations
Click cells to compare fundamentals
AstraZeneca PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AstraZeneca PLC cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (621M) | 1.6B | 3.9B | (669M) | (769.4M) | (730.9M) | |
| Change In Cash | 2.3B | (1.5B) | (55M) | (346M) | (311.4M) | (327.0M) | |
| Free Cash Flow | 2.2B | 3.8B | 7.2B | 6.6B | 7.6B | 7.9B | |
| Change In Working Capital | 361M | 2.0B | 3.8B | 300M | 345M | 177.9M | |
| Begin Period Cash Flow | 5.2B | 7.5B | 6.0B | 6.0B | 6.9B | 4.5B | |
| Other Cashflows From Financing Activities | (101M) | (178M) | (297M) | (1.2B) | (1.0B) | (986.7M) | |
| Depreciation | 3.1B | 6.5B | 5.5B | 4.9B | 5.7B | 6.0B | |
| Other Non Cash Items | (2.6B) | (2.3B) | (1.9B) | (2.4B) | (2.1B) | (2.2B) | |
| Capital Expenditures | 2.6B | 2.2B | 2.6B | 3.8B | 4.3B | 4.6B | |
| Total Cash From Operating Activities | 4.8B | 6.0B | 9.8B | 10.3B | 11.9B | 12.5B | |
| Net Income | 3.9B | (265M) | 2.5B | 6.9B | 7.9B | 4.4B | |
| Total Cash From Financing Activities | (2.2B) | 3.6B | (6.8B) | (6.6B) | (5.9B) | (5.6B) | |
| End Period Cash Flow | 7.5B | 6.0B | 6.0B | 5.6B | 6.5B | 4.1B | |
| Other Cashflows From Investing Activities | 87M | 54M | 60M | (1.5B) | (1.7B) | (1.7B) | |
| Sale Purchase Of Stock | 3.0B | 12.4B | (920M) | 3.7B | 4.3B | 4.5B | |
| Change To Account Receivables | (739M) | (961M) | (1.3B) | (1.4B) | (1.3B) | (1.2B) | |
| Dividends Paid | 3.6B | 3.9B | 4.4B | 4.5B | 5.2B | 3.4B | |
| Stock Based Compensation | 277M | 615M | 619M | 579M | 665.9M | 340.4M | |
| Investments | 2.0B | 605M | (3.0B) | (4.1B) | (3.7B) | (3.5B) | |
| Net Borrowings | (1.7B) | 1.4B | 7.7B | (1.4B) | (1.3B) | (1.2B) | |
| Total Cashflows From Investing Activities | (657M) | (285M) | (11.1B) | (3.0B) | (3.4B) | (3.6B) | |
| Change To Netincome | (816M) | (1.7B) | (615M) | (2.5B) | (2.2B) | (2.4B) | |
| Change To Liabilities | 868M | 1.7B | 1.4B | 1.2B | 1.3B | 896.3M | |
| Issuance Of Capital Stock | 3.5B | 30M | 29M | 33M | 29.7M | 28.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Other Information on Investing in AstraZeneca Stock
The Cash Flow Statement is a financial statement that shows how changes in AstraZeneca balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which AstraZeneca's non-liquid assets can be easily converted into cash.